COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals

Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Base...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavda, Vivek P., Vora, Lalitkumar K., Vihol, Disha R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. on behalf of Zhejiang Chinese Medical University. 2021
Materias:
Views on News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351577/
http://dx.doi.org/10.1016/j.ccmp.2021.100004
Descripción
Sumario:Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19Ⓡ vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.

Ejemplares similares